



Ofirmev® (acetaminophen) – First-time generic

- On December 7, 2020, [Leucadia Pharmaceuticals](#) and Auromedics/Aurobindo launched [AP-rated](#) generic versions of Mallinckrodt's [Ofirmev \(acetaminophen\)](#) intravenous solution.
 - On March 22, 2016, Sandoz received FDA approval of an [AP-rated](#) generic version of Ofirmev. Launch plans are pending.
 - On August 7, 2020, Mylan received FDA approval of an [AP-rated](#) generic version of Ofirmev. Launch plans are pending.
- Ofirmev is approved for the management of mild to moderate pain in adult and pediatric patients 2 years and older; the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older; and the reduction of fever in adult and pediatric patients.
- Ofirmev carries a boxed warning for risk of medication errors and hepatotoxicity.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.